Lotus Pharmaceutical Co., Ltd.

TWSE:1795 Voorraadrapport

Marktkapitalisatie: NT$70.0b

Lotus Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Lotus Pharmaceutical heeft een totaal eigen vermogen van NT$18.5B en een totale schuld van NT$10.4B, wat de schuld-eigenvermogensverhouding op 56.1% brengt. De totale activa en totale passiva bedragen respectievelijk NT$34.6B en NT$16.2B. De EBIT Lotus Pharmaceutical is NT$4.7B waardoor de rentedekking 9.5 is. Het heeft contanten en kortetermijnbeleggingen van NT$2.9B.

Belangrijke informatie

56.1%

Verhouding schuld/eigen vermogen

NT$10.37b

Schuld

Rente dekkingsratio9.5x
ContantNT$2.86b
AandelenNT$18.48b
Totaal verplichtingenNT$16.16b
Totaal activaNT$34.64b

Recente financiële gezondheidsupdates

Recent updates

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Oct 23
Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$14.2B ) 1795 } overtreffen de korte termijn passiva ( NT$6.6B ).

Langlopende schulden: De kortetermijnactiva 1795 ( NT$14.2B ) overtreffen de langetermijnschulden ( NT$9.6B ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 40.7% ) 1795 wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 1795 is de afgelopen 5 jaar gedaald van 87.9% naar 56.1%.

Schuldendekking: De schuld van 1795 wordt goed gedekt door de operationele kasstroom ( 39.3% ).

Rentedekking: De rentebetalingen op de schuld van 1795 worden goed gedekt door EBIT ( 9.5 x dekking).


Balans


Ontdek gezonde bedrijven